Ticker brief · 2026-08-16
TENX
Failed Phase 3 leaves TENX broken, with only bounce traders
Lean: bearishlast close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
9
authors 14d
7
crowd 14d
-1.2σ
TENX is decisively bearish, with high-credibility biotech voices confirming a broad Phase 3 failure while the sole bounce call comes from a cold-hand trader. The late-week shift was evidence that actual shares held fell about 30% despite exercisable options obscuring the reduction. Trade structure favors avoiding binary exposure, with only conditional post-result dip buying or a short-lived dead-cat bounce under consideration.
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
BULL CAMP
The bull case is purely technical: a 90% one-day collapse could produce a dead-cat bounce, without evidence that the fundamental thesis has recovered.
Key voices@Mitch___PicksMEDIUMC-2.60
“A dead-cat bounce may follow the 90% one-day decline, although no entry was specified.”— @Mitch___Picks · tweet ↗
BEAR / SKEPTIC
TNX-103 missed its Phase 3 primary and key symptom endpoints, leaving a narrow prospective FDA path and widespread evidence of thesis destruction. The 85%-90% collapse and subsequent ownership reduction reinforce the fundamental damage.
Key voices@adamfeuersteinHIGHA+1.41@OpenOutcrierMEDIUM-HIGHC@BPharmCatalystMEDIUM-HIGHC@FiercePharmaMEDIUM-HIGHB-1.09@BiomavenMEDIUM-HIGHA+1.79
“TENX Phase 3 missed statistical significance on its primary endpoint.”— @adamfeuerstein · tweet ↗
Hypotheses7direction · basis · magnitude · supporters — NEW = first seen this week
▼TNX-103 Phase 3 LEVEL missed its primary and key symptom endpoints, materially breaking the drug's efficacy thesis.
@adamfeuersteinHIGHA+1.412s · insight@OpenOutcrierMEDIUM-HIGHC1s@BPharmCatalystMEDIUM-HIGHC1s@BioStocksMEDIUM-HIGHC-3.021s@CryptoNewsHntrsLOW-MEDIUMC-1.001s@EmmanuelInvestLOW-MEDIUMC-1.111s+7 more
▼The failed Phase 3 leaves levosimendan with only a narrow prospective FDA path despite management asserting a way forward.
@FiercePharmaMEDIUM-HIGHB-1.091s@fwpharmaMEDIUM-HIGHB+0.981s@PersimmonTIMEDIUM-HIGHA-0.571s · insight@Maximus_HollaLOW-MEDIUMC+0.801s
▼Patient selection contributed materially to the TENX trial failure, indicating that trial design compounded the drug's inherent development risk.
@BiomavenMEDIUM-HIGHA+1.791s · insight
▼The 80%-90% post-readout collapse reflects immediate technical and market confirmation that the prior TENX equity thesis was destroyed.
@PharmdcaMEDIUM-HIGHC+0.822s@OpenOutcrierMEDIUM-HIGHC1s@CryptoNewsHntrsLOW-MEDIUMC-1.001s@EngSam0701MEDIUMC+1.881s@FinanchleMEDIUMC1s@HedgeyeHIGHB-2.551s · insight+5 more
◆TENX-style binary readouts should not be held through the event; exposure is preferable only after positive data and a dip.
@PharmdcaMEDIUM-HIGHC+0.822s@bioinvestor24MEDIUM-HIGHA-0.452s · insight@BottomPhishingLOW-MEDIUMB-1.201s · insight
▲TENX could stage a short-lived dead-cat bounce after its 90% one-day decline despite the absence of fundamental recovery.
@Mitch___PicksMEDIUMC-2.601s
▼Actual shares held fell about 30%, while exercisable options obscured the reduction and weakened the apparent ownership signal.
@AponiaAnalyticsLOW-MEDIUMB+4.911s · insight
Direct calls2authors taking explicit directional positions
@PharmdcaMEDIUM-HIGHC+0.82
Avoid TENX-style binary-event gambles and favor better risk-reward setups.
@PharmdcaMEDIUM-HIGHC+0.82
Buy only after positive results and a subsequent dip; do not hold through binary readouts.
Sellside activity1
Bernstein SocGen pt_raise PT 554 (from 430)Raised TSM's target to 554 from 430 amid strong revenue growth; this mention is unrelated to TENX.
News / data points5discrete events + data quoted by authors
@adamfeuersteinHIGHA+1.41
TENX Phase 3 missed statistical significance on its primary endpoint.
@BPharmCatalystMEDIUM-HIGHC
The Phase 3 trial missed both its primary and key symptom endpoints.
@OpenOutcrierMEDIUM-HIGHC
The study failed to improve walking results, sending shares down 85% premarket.
@FiercePharmaMEDIUM-HIGHB-1.09
Levosimendan failed Phase 3, leaving a narrow prospective FDA path.
@AponiaAnalyticsLOW-MEDIUMB+4.91
Actual shares held fell about 30%, while exercisable options obscured the reduction.
Position disclosures1skin in the game
@PortfolioArmorMEDIUM-HIGHC-1.71
Reported TENX remained open after completed ABCL and TXG exits.
Desk readconvergence assessment
Views are highly converged around clinical failure and severe thesis impairment; the disagreement is limited to whether a 90% collapse creates a tradable bounce. The bear camp includes high-credibility, stronger-reading sources, while the only explicit bounce advocate has a -2.1 trader_score_20; several bearish voices are also cold, including Hedgeye at -2.1, so the trial data matter more than recent trading records. A credible FDA salvage route, viable confirmatory plan, or new efficacy evidence would be required to change the fundamental view.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 168% | HV n/a |
| Skew — 25Δ RR 30d | +0.245 | 25Δ call IV − put IV |
| OI alarm | quiet | last alarm 2026-07-06 (z=3.0) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-25 · now +0.30 (−1 bearish … +1 bullish)
Who spoke7
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @SuperDuperInvst | C | -0.99 | 2 | -0.07 |
| @zohmbastic | C | -1.38 | 2 | +0.23 |
| @AponiaAnalytics | B | +4.91 | 1 | -0.25 |
| @BiopharmIQ | B | · | 1 | -0.60 |
| @majgeoinvesting | A | +0.67 | 1 | -0.75 |
| @abc51648039 | C | -1.29 | 1 | +0.25 |
| @Angeleno551 | C | -1.03 | 1 | +0.35 |
Recent signals9of 9 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-25 | @zohmbastic | +0.30 | Reports a 0.036 put-call ratio for TENX. | · | tweet ↗ |
| 2026-08-25 | @Angeleno551 | +0.35 | Anticipates TENX filling a chart gap but gives no explicit entry intent. | · | tweet ↗ |
| 2026-08-25 | @abc51648039 | +0.25 | Lists TENX bullish trigger, two resistance targets and support. | · | tweet ↗ |
| 2026-08-24 | @zohmbastic | +0.15 | Reports an approximately $1.8 million Adar1 Capital position associated with TENX. | · | tweet ↗ |
| 2026-08-24 | @SuperDuperInvst | +0.10 | Presents a speculative buyout and strategic-investment thesis for VBIO. | · | tweet ↗ |
| 2026-08-23 | @SuperDuperInvst | -0.25 | Strongly advocates that TENX acquire VBIO, while noting TENX's failed Phase 3 trial. | · | tweet ↗ |
| 2026-08-23 | @majgeoinvesting | -0.75 | TENX fell from $13 to $1 in one day following weak Phase 3 trial data. | · | tweet ↗ |
| 2026-08-17 | @BiopharmIQ | -0.60 | Weekly biotech digest reports merger, trial, acquisition and competitive developments across named firms. | · | tweet ↗ |
| 2026-08-15 | @AponiaAnalytics | -0.25 | Reports actual shares held fell about 30% while exercisable options obscured the reduction | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.